Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.
暂无分享,去创建一个
P. Park | T. Jacks | R. Weissleder | U. Mahmood | D. Kirsch | Yoon-Jin Lee | J. Dreyfuss | S. Ryeom | P. Waterman | Sam S. Yoon | G. Nielsen | R. Dodd | L. Stangenberg | Kwan-Hyuck Baek | C. Rothrock | Carolyn J Fisher
[1] F. McKeon,et al. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. , 2008, Cancer cell.
[2] S. Nie,et al. Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .
[3] C. Johannessen,et al. TORC1 Is Essential for NF1-Associated Malignancies , 2008, Current Biology.
[4] D. Hallahan,et al. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. , 2007, International journal of radiation oncology, biology, physics.
[5] G. Demetri,et al. Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.
[6] N. Andratschke,et al. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. , 2007, Reviews on recent clinical trials.
[7] Jan Grimm,et al. A spatially and temporally restricted mouse model of soft tissue sarcoma , 2007, Nature Medicine.
[8] Vasilis Ntziachristos,et al. Tomographic fluorescence imaging of tumor vascular volume in mice. , 2007, Radiology.
[9] G. Parker,et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.
[10] P. Park,et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. , 2006, The Journal of surgical research.
[11] M. Neeman,et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. , 2006, Cancer cell.
[12] D. Gutmann,et al. Harnessing preclinical mouse models to inform human clinical cancer trials. , 2006, The Journal of clinical investigation.
[13] N. Segal,et al. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. , 2005, Cancer research.
[14] D. Sahani,et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. , 2005, Radiology.
[15] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[16] Jonathan R. Lindner,et al. Imaging Tumor Angiogenesis With Contrast Ultrasound and Microbubbles Targeted to &agr;v&bgr;3 , 2003 .
[17] Gerald McMahon,et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.
[18] A. Dicker,et al. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] Chun Xing Li,et al. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] W. Kruskal,et al. Use of Ranks in One-Criterion Variance Analysis , 1952 .
[21] D. Hume,et al. Characterisation and trophic functions of murine embryonic macrophages based upon the use of a Csf1r-EGFP transgene reporter. , 2007, Developmental biology.
[22] Jiri Sklenar,et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. , 2003, Circulation.
[23] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] S. Eidt,et al. Cyclin-dependent kinase-inhibitor 1 (CDKN1A) in the squamous epithelium of the oropharynx: possible implications of molecular biology and compartmentation. , 2001, Anticancer research.